BERKELEY, Calif. and , Jan. 14, 2026 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, is excited to announce its participation in the upcoming American Association for Cancer Research (AACR) 2026 Annual Meeting. This prestigious conference will be held April 17 to 22, 2026, in San Diego, California. Organized by the American Association for Cancer Research, this premier event gathers scientists, clinicians, and industry leaders from around the world to share groundbreaking cancer research and explore new approaches in oncology.

At AACR the Company will present the results of its verification study evaluating a compact proprietary combination of blood-derived mRNA biomarkers and an AI-assisted modeling approach designed to differentiate PDAC from benign conditions including IPMNs in a 30-subject cohort.

Further details will be published in the online Proceedings of the AACR .

The Company looks forward to present the results of this study at AACR as it aims to revolutionize pancreatic cancer screening practices and contribute to a reduction in cancer mortality rates worldwide.

Please visit Mainz Biomed’s official website for investors at mainzbiomed.com/investors/ for more information

Please follow us to stay up to date:
LinkedIn
X (Previously Twitter)
Facebook

About Mainz Biomed NV

Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert ® , an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer. ColoAlert ® is marketed across Europe. The Company is currently running its eAArly DETECT 2 clinical study in preparation for its pivotal FDA study for US regulatory approval. Mainz Biomed’s product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in blood and stool samples. To learn more, visit mainzbiomed.com or follow us on LinkedIn , Twitter and Facebook .

For media inquiries as to Mainz Biomed:
MC Services AG
Maximilian Schur / Simone Neeten
+49 211 529252 20
[email protected]

For investor inquiries, please contact [email protected]

Forward-Looking Statements

Certain statements made in this press release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “expect”, “estimate”, “plan”, “outlook”, and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, actual results may differ materially from the Company’s expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) the failure to meet projected development and related targets; (ii) changes in applicable laws or regulations; (iii) the effect of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the “SEC”) by the Company. Additional information concerning these and other factors that may impact the Company’s expectations and projections can be found in its initial filings with the SEC, including its annual report on Form 20-F filed on March 31, 2025 and its mid-year report on Form 6-K filed on September 26, 2025. The Company’s SEC filings are available publicly on the SEC’s website at www.sec.gov. Any forward-looking statement made by us in this press release is based only on information currently available to Mainz Biomed and speaks only as of the date on which it is made. Mainz Biomed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.